FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Provided By GlobeNewswire
Last update: Dec 9, 2024
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo
Read more at globenewswire.comNASDAQ:MCRB (12/15/2025, 8:00:02 PM)
15.9
-1.04 (-6.14%)
Find more stocks in the Stock Screener
